1. Home
  2. TSVT

as 04-18-2025 1:44pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

Founded: 2021 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 258.9M IPO Year: N/A
Target Price: $6.50 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.10 EPS Growth: N/A
52 Week Low/High: $2.29 - $5.30 Next Earning Date: 05-07-2025
Revenue: $37,862,000 Revenue Growth: -62.28%
Revenue Growth (this year): 84.48% Revenue Growth (next year): 9.69%

TSVT Daily Stock ML Predictions

Stock Insider Trading Activity of 2seventy bio Inc. (TSVT)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Snow Jessica TSVT Chief Operating Officer Mar 17 '25 Sell $4.95 2,298 $11,363.61 254,193
Baird William D III TSVT President and CEO Mar 17 '25 Sell $4.95 5,092 $25,179.94 1,121,034
Eatwell Victoria TSVT Chief Financial Officer Mar 17 '25 Sell $4.95 2,592 $12,817.44 444,387
Kynam Global Healthcare Master Fund, LP TSVT 10% Owner Mar 11 '25 Sell $4.93 16,238,047 $80,053,571.71 0

Share on Social Networks: